Thermo Fisher Scientific Inc ($TMO) Stock Forecast: Down 10.0% Today

What is Thermo Fisher Scientific Inc?

Thermo Fisher Scientific (TMO) is a leading company based in Waltham, known for its scientific instruments, reagents, and consumables. The company operates globally and has been focusing on strategic growth initiatives.

Why is Thermo Fisher Scientific Inc going down?

TMO stock is down 10.0% on Apr 23, 2026 19:46

• Thermo Fisher's stock experienced a bearish movement despite beating first-quarter earnings estimates, primarily due to concerns over modest organic growth and a cautious outlook.
• The company's reliance on acquisitions for revenue growth, with organic growth at only 1%, raised investor worries about sustainable future growth prospects.
• The CEO's optimistic comments about benefiting from domestic manufacturing efforts and strategic collaborations were overshadowed by the market's focus on underlying growth challenges and revenue outlook concerns.
• The bearish trend might have been further exacerbated by profit-taking behavior following the recent stock repurchases and dividend increase, as investors reevaluated the company's overall growth trajectory.

TMO Price Chart

TMO Technical Analysis

TMO News

Thermo Fisher CEO says onshoring push will bring a ‘tailwind’ for the Waltham company

Thermo Fisher Scientific CEO Marc Casper stated that the Waltham-based company is already benefiting from domestic manufacturing efforts, anticipating further growth in the coming years. This "tailwind" is expected to be buoyed by onshoring initiatives, with former President Donald Trump having recently toured a Thermo Fisher facility to highlight his administration's focus on lowering drug prices and boosting domestic production.

https://www.bizjournals.com/boston/news/2026/04/23/thermo-fisher-us-manufacturing.html

Thermo Fisher falls after earnings top estimates, but growth concerns persist

Thermo Fisher Scientific's shares fell over 7.5% despite beating first-quarter earnings estimates, as investors focused on modest underlying organic growth and a cautious outlook. While adjusted earnings per share and revenue both exceeded expectations, acquisitions drove a significant portion of the revenue increase, with organic growth at only 1%. The company raised its full-year revenue outlook but it remains slightly below consensus estimates, contributing to investor concerns about future growth.

https://www.proactiveinvestors.com/companies/news/1091089/thermo-fisher-falls-after-earnings-top-estimates-but-growth-concerns-persist-1091089.html

Cumberland Pharmaceuticals to sell branded drug unit to Apotex for $100M

Cumberland Pharmaceuticals announced an agreement to sell its branded pharmaceutical line to an affiliate of Apotex for $100 million in cash, a deal representing more than twice Cumberland’s current market capitalization. The company will retain its product pipeline and its majority ownership in Cumberland Emerging Technologies Inc. Cumberland is actively developing ifetroban, a thromboxane antagonist, through three separate programs, including one for Duchenne muscular dystrophy with FDA designations.

https://www.investing.com/news/company-news/cumberland-pharmaceuticals-to-sell-branded-drug-unit-to-apotex-for-100m-93CH-4632724

GE HealthCare to Post Q1 Earnings: What's in Store for the Stock?

GE HealthCare Technologies Inc. (GEHC) is set to report its first-quarter 2026 earnings on April 29, with analysts anticipating sustained low-to-mid-single-digit organic revenue growth despite challenges in China and tariff-related costs. The company's prior quarter showed an earnings beat, and the upcoming report is expected to highlight strong performance in Pharmaceutical Diagnostics and stable growth in Imaging. However, a neutral Earnings ESP and a Zacks Rank #3 suggest the prediction for an earnings beat is not strong, despite positive estimates for revenue and EPS growth.

https://www.tradingview.com/news/zacks:79dcafb13094b:0-ge-healthcare-to-post-q1-earnings-what-s-in-store-for-the-stock/

Thermo Fisher Scientific Reports First Quarter 2026 Results

Thermo Fisher Scientific reported strong first-quarter 2026 results, with revenue up 6% to $11.01 billion and diluted EPS growing 11% to $4.43. The company highlighted new product launches, strategic collaborations with NVIDIA and SHL Medical, and the acquisition of Clario, along with stock repurchases and a dividend increase. Thermo Fisher CEO Marc N. Casper emphasized excellent execution, the company's PPI Business System, and its commitment to driving innovation and customer success.

https://www.pharmiweb.com/press-release/2026-04-23/thermo-fisher-scientific-reports-first-quarter-2026-results

Trending Today

Thermo Fisher Scientific Inc Price History

01.07.2025 - TMO Stock was down 5.1%

• The decline in Thermo Fisher Scientific's stock today may be linked to the adoption of a bearish stance by influential investors, as reflected in options trading activities.
• While TMO has consistently outperformed the market in the long run, short-term market sentiment and investor behavior can impact daily fluctuations.
• Investors might be capitalizing on gains or adjusting their positions in response to prevailing market conditions or internal company developments, influencing the stock's downward trajectory today.
• It is crucial for investors to assess both TMO's long-term growth prospects and the short-term market dynamics to make well-informed investment choices.

29.00.2026 - TMO Stock was down 5.2%

• Thermo Fisher (TMO) experienced a bearish movement despite reporting better-than-expected Q4 CY2025 results, with revenue surpassing analyst estimates and strong performance in its Life Sciences Solutions segment.
• The stock might have faced downward pressure due to profit-taking by investors following the immediate stock increase post-earnings report.
• The overall market sentiment could have been influenced by broader market conditions or sector rotation, leading to the bearish movement in TMO's stock price today.
• It's possible that investors were expecting even stronger guidance or future outlook from the company, causing some disappointment and resulting in the bearish market movement.

23.03.2026 - TMO Stock was down 10.0%

• Thermo Fisher's stock experienced a bearish movement despite beating first-quarter earnings estimates, primarily due to concerns over modest organic growth and a cautious outlook.
• The company's reliance on acquisitions for revenue growth, with organic growth at only 1%, raised investor worries about sustainable future growth prospects.
• The CEO's optimistic comments about benefiting from domestic manufacturing efforts and strategic collaborations were overshadowed by the market's focus on underlying growth challenges and revenue outlook concerns.
• The bearish trend might have been further exacerbated by profit-taking behavior following the recent stock repurchases and dividend increase, as investors reevaluated the company's overall growth trajectory.

23.03.2026 - TMO Stock was down 11.0%

• Thermo Fisher Scientific reported strong first-quarter results with revenue and earnings growth, driven by acquisitions and new product launches.
• Despite beating earnings estimates, the stock experienced a bearish movement due to concerns over modest organic growth and a cautious full-year revenue outlook.
• Investors focused on the company's reliance on acquisitions for revenue increase and the slightly below-consensus full-year revenue guidance, leading to the stock decline.
• The market reaction suggests that while the company's financials are solid, concerns about future organic growth and demand are weighing on investor sentiment, resulting in the bearish movement of the stock.

23.03.2026 - TMO Stock was down 10.5%

• Thermo Fisher Scientific's stock saw a bearish trend due to weaker-than-expected organic growth, which raised concerns about demand despite exceeding revenue and EPS expectations.
• The market reacted negatively to the company's reliance on acquisitions for growth, with organic revenue growth at only 1%, indicating a preference for sustainable core business performance.
• Despite successful capital deployment, new product launches, and strategic partnerships, investors prioritized the quality of underlying business growth over the earnings beat, leading to the stock decline.
• The bearish movement highlights the market's emphasis on sustainable growth and operational excellence rather than short-term financial metrics, impacting Thermo Fisher's stock performance negatively.

30.08.2025 - TMO Stock was up 3.8%

• The positive market response to TMO's bond offering suggests investor confidence in the company's financial stability.
• The continued bullish interest from financial institutions and traders signals strong belief in Thermo Fisher Scientific's growth potential.
• Overall, TMO's bullish performance today could be linked to the successful bond offering and positive market sentiment.

02.00.2026 - TMO Stock was up 2.2%

• The global single-use bioprocessing products market is expected to witness substantial growth, with Thermo Fisher Scientific Inc. playing a significant role in the industry's advancement, contributing to the optimistic market trends.
• Noteworthy increases in stakes by Allspring Global Investments Holdings LLC and Ninety One UK Ltd in TMO reflect a growing confidence in the company's future, potentially influencing a rise in the stock's value.
• Despite recent significant insider sales, the company's impressive quarterly earnings report surpassing expectations, coupled with the initiation of a new stock buyback program and quarterly dividend declaration, have likely bolstered investor trust in TMO.
• The collective institutional interest and portfolio adjustments by different investment entities indicate a favorable outlook for TMO, aligning with the current bullish market movement.

18.11.2025 - TMO Stock was down 2.4%

• The decline in TMO stock may be linked to profit-taking by institutional investors actively trading the stock.
• Despite positive updates on strong quarterly earnings and a $5 billion share buyback program, concerns arose among investors due to insider selling by the CEO and COO, potentially contributing to the stock's downward trend.
• Weak performance by West Pharmaceutical Services (WST) in the healthcare sector could have also impacted investor sentiment towards TMO, as some may have shifted away from underperforming healthcare stocks.
• In sum, today's bearish movement in TMO stock seems influenced by profit-taking, insider selling concerns, and broader sector trends affecting investor outlook.

23.06.2025 - TMO Stock was up 12.4%

• Q2 earnings and revenues of Thermo Fisher Scientific exceeded expectations, propelled by successful product launches and robust segment growth, resulting in a notable increase in the stock price.
• Notable bullish sentiment was observed in the options trends for TMO, with a majority of traders expressing optimism about the stock.
• Investors are placing emphasis on the growth prospects of Thermo Fisher's Analytical Instruments segment, foreseeing its positive impact on performance in the upcoming quarters.
• The optimistic outlook from major investors towards TMO, reflected through options activity, likely played a role in the stock's favorable market trajectory today.

12.01.2026 - TMO Stock was down 5.2%

• Varma Mutual Pension Insurance Co and Cornerstone Investment Partners LLC increased their holdings in TMO, showing confidence in the company's future prospects.
• ING Groep NV and Atria Investments Inc reduced their stakes in TMO, possibly due to profit-taking or portfolio rebalancing.
• The initiation of a $5 billion stock repurchase plan by Thermo Fisher Scientific may have influenced market sentiment, signaling management's belief in the company's undervaluation.
• Despite the mixed institutional activity and insider sales, analysts maintain a "Moderate Buy" rating for TMO, with an average price target of $633.68, reflecting positive quarterly earnings and growth potential.

14.03.2026 - TMO Stock was up 5.0%

• Thermo Fisher Scientific's stock surged 3.6% today, indicating a bullish trend.
• The collaboration with HealthVerity to enhance real-world data capabilities shows the company's commitment to advancing clinical research and evidence generation.
• The undervaluation of TMO compared to its GF Value™ and the strong GF Score™ of 88 highlight positive performance metrics despite insider selling, signaling potential challenges ahead.
• The focus on precision medicine growth through collaborations like PRECISE-SG100K biobank positions TMO well for long-term success in the evolving healthcare landscape.

01.09.2025 - TMO Stock was up 9.2%

• The stock of Thermo Fisher Scientific showed a strong upward trend today, likely influenced by a noteworthy Power Inflow alert, reflecting optimistic sentiment from institutional and retail investors.
• The company's decision to initiate a four-part bond offering in anticipation of a potential government shutdown might have also played a part in the positive trend, demonstrating proactive financial preparation and stability.
• The optimistic actions of financial institutions and the prevailing bullish sentiment among traders regarding TMO all contributed to the favorable momentum, underscoring confidence in the company's future prospects.